▲ +6.89% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Generation Bio in the last 3 months. The average price target is $32.33, with a high forecast of $38.00 and a low forecast of $28.00. The average price target represents a 6.89% upside from the last price of $30.25.
The current consensus among 4 polled investment analysts is to buy stock in Generation Bio.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.